^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD19-targeted CAR-T immunotherapy

    Related drugs:
    19h
    M-2024-424: MB-CART2019.1 in refractory MS (2024-517601-82-00)
    P1/2, N=25, Recruiting, Miltenyi Biomedicine GmbH | Not yet recruiting --> Recruiting
    Enrollment open
    |
    zamtocabtagene autoleucel (MB-CART2019.1)
    22h
    CARMEN-803: N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas (clinicaltrials.gov)
    P1, N=0, Withdrawn, University of Utah | N=13 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    Anktiva (nogapendekin alfa inbakicept-pmln)
    1d
    A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov)
    P1, N=64, Recruiting, Capstan Therapeutics | N=38 --> 64 | Trial completion date: Feb 2026 --> Nov 2027 | Trial primary completion date: Feb 2026 --> Nov 2027
    Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    1d
    Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=51, Active, not recruiting, City of Hope Medical Center | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    CD19 CAR T cells
    1d
    A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies (clinicaltrials.gov)
    P1/2, N=50, Not yet recruiting, Sheba Medical Center
    New P1/2 trial
    |
    TP53 (Tumor protein P53) • CD19 (CD19 Molecule) • KMT2A (Lysine Methyltransferase 2A) • TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1)
    3d
    NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) (clinicaltrials.gov)
    P2/3, N=40, Recruiting, Health Institutes of Turkey
    New P2/3 trial
    |
    CD19 (CD19 Molecule) • CCND1 (Cyclin D1)
    |
    Chr t(11;14)
    3d
    A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=30, Recruiting, Suzhou Immunofoco Biotechnology Co., Ltd | Phase classification: P1/2 --> P1
    Phase classification
    |
    CD19 positive • CD20 negative
    3d
    Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL (clinicaltrials.gov)
    P1/2, N=50, Recruiting, Peking University People's Hospital | N=30 --> 50 | Trial completion date: Dec 2026 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CD22 (CD22 Molecule)
    |
    cyclophosphamide • fludarabine IV
    4d
    Transpocall19: Single-center phase I/IIa study with CART cells produced using the anti-CD19 transposon technique (TranspoCART19) for patients with CD19+ acute lymphoblastic leukemia resistant or refractory to treatment (2025-522673-11-00)
    P1/2, N=24, Recruiting, Clinica Universidad De Navarra | Not yet recruiting --> Recruiting
    Enrollment open
    4d
    A multiCenter phase I study of aUtologous CD19 CAR T cElls for therapy refractory chronic GvHD (CURE-cGvHD) (2025-524468-40-00)
    P1, N=14, Not yet recruiting, Universitaetsklinikum Erlangen AR
    New P1 trial
    5d
    Co-administration of CART22-65s and huCART19 for B-ALL (clinicaltrials.gov)
    P1/2, N=93, Recruiting, Stephan Grupp MD PhD | Trial completion date: Jan 2029 --> Jul 2029 | Trial primary completion date: Jan 2027 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    CD22 (CD22 Molecule)
    |
    CART22 • huCART19